Physician profile
Kunal Kishorkumar Parekh
NPI 1205141793
$171,776.43
in general payments reported to CMS, 2019-2025
25 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $562 · 2021: $21K · 2022: $47K · 2023: $15K · 2024: $35K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Food and Beverage: $5,717 · Consulting Fee: $4,100 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,100 · Travel and Lodging: $1,827 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,353.50 |
| Food and Beverage | $5,716.58 |
| Consulting Fee | $4,100.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,100.00 |
| Travel and Lodging | $1,826.91 |
| Education | $122.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $122,654.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $24,974.73 | 2020-2025 | Benlysta |
| Travere Therapeutics, INC. | $16,444.23 | 2019-2025 | Filspari |
| Calliditas Therapeutics US INC. | $1,887.19 | 2022-2025 | Tarpeyo |
| Amarin Pharma, INC. | $1,066.53 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,057.10 | 2019-2025 | Farxiga, Andexxa |
| Amgen INC. | $908.42 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $570.57 | 2019-2025 | |
| Novo Nordisk INC | $531.54 | 2021-2025 | Ozempic, Rybelsus, Rivfloza |
| Nxstage Medical, INC. | $340.71 | 2019-2022 | |
| Baxter Healthcare | $319.49 | 2021-2024 | Renal - Acute |
| Ardelyx, INC. | $288.01 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Mallinckrodt Hospital Products INC. | $220.24 | 2021-2023 | Acthar |
| Outset Medical INC | $140.31 | 2021 | |
| Vifor Pharma, INC. | $67.60 | 2020-2023 | Veltassa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $45.13 | 2021-2022 | |
| Akebia Therapeutics INC | $43.89 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.62 | 2025 | Livtencity |
| Otsuka America Pharmaceutical, INC. | $33.46 | 2019 | |
| Kyowa Kirin, INC. | $33.00 | 2023 | |
| Aurinia Pharma U.S., INC. | $24.15 | 2022 | |
| Cormedix INC. | $23.19 | 2024 | Defencath |
| Amicus Therapeutics, INC. | $22.70 | 2020 | |
| Mallinckrodt Enterprises LLC | $22.51 | 2019 | |
| Fresenius USA Marketing, INC. | $22.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.